Fibroblast growth factor

Kriya Acquires Tramontane Therapeutics and Launches Gene Therapy Program for Nonalcoholic Steatohepatitis (NASH) and Other Prevalent Diseases

Retrieved on: 
Wednesday, September 6, 2023
Obesity, NASH, Half-life, PALO, Type 1 diabetes, Research, FGF21, AAV, UAB, RESEARCH, Fibrosis, Molecular biology, Instituto Universitario de Restauración del Patrimonio of the Universitat Politècnica de València, Fibroblast growth factor, PARK, Liver, Tramontane, Entrepreneurship, DSM-IV codes, Therapy, Disease, Safety, Conditional sentence, Pharmaceutical industry, Vaccine, Biochemistry, Kriyā

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc., ("Kriya") a biopharmaceutical company developing gene therapies for conditions affecting millions of people around the world, today announced that it has acquired Tramontane Therapeutics, Inc. ("Tramontane"). Tramontane is a private gene therapy company focused on developing treatments for metabolic and neurodegenerative diseases. Tramontane, a spin out from Universitat Autònoma de Barcelona (UAB), is now a wholly owned subsidiary of Kriya.

Key Points: 
  • Tramontane is a private gene therapy company focused on developing treatments for metabolic and neurodegenerative diseases.
  • Tramontane, a spin out from Universitat Autònoma de Barcelona (UAB), is now a wholly owned subsidiary of Kriya.
  • "The addition of Tramontane’s FGF21 program strategically aligns with our Metabolic Disease portfolio which also includes a one-time gene therapy candidate for insulin-dependent diabetes."
  • I believe that a one-time gene therapy would be a quantum leap forward in the management of this chronic disease."

Trefoil Therapeutics’ Lead Investigational Candidate TTHX1114 Improves Rate of Visual Recovery after Descemet Stripping Only (DSO) in Phase 2 STORM Data Presented at ASCRS Annual Meeting

Retrieved on: 
Monday, May 8, 2023
Health, Surgery, General Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Fuchs, Abstract, Cornea, Descemet's membrane, Mayo Clinic, Refractive surgery, Epithelium, Fibroblast growth factor, CCT, Quality of life, Endothelium, Hope, Research, ASCRS, DSO, Fuchs' dystrophy, American Society of Cataract and Refractive Surgery, Risk, FGF1, Annual general meeting, Disease, Cataract, GLARE, Therapy, Society, Safety, Fibroblast growth factor receptor 2, Pharmaceutical industry, Medical imaging, Patient

A separate STORM analysis assessed visual morbidity in patients with Fuchs endothelial corneal dystrophy (FECD) prior to surgery using the V-Fuchs Questionnaire (V-FUCHS).

Key Points: 
  • A separate STORM analysis assessed visual morbidity in patients with Fuchs endothelial corneal dystrophy (FECD) prior to surgery using the V-Fuchs Questionnaire (V-FUCHS).
  • The data were presented at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in San Diego.
  • The study results showed TTHX1114 improved best-corrected visual acuity (BCVA) and central corneal thickness (CCT) after DSO in the 49 subjects/64 eyes.
  • Faster recovery was associated with smaller descemetorhexis (surgical removal of Descemet membrane), while comorbid diabetes appeared to delay recovery.

Trefoil Therapeutics Announces TTHX1114 Data Presentations at the Annual Association for Research in Vision and Ophthalmology (ARVO) Meeting

Retrieved on: 
Monday, April 17, 2023
Health, Health Technology, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Fuchs, ARVO, Cornea, Lycée Français de la Nouvelle-Orléans, Research, DSO, Patient, Role, Therapy, Endothelium, Fibroblast growth factor, Medical imaging, Ophthalmology

Trefoil Therapeutics , a clinical-stage biotechnology company focused on restoring sight to people with corneal diseases, today announced multiple presentations providing evidence for clinical and preclinical efficacy of the company’s investigational medicine TTHX1114 for improving visual outcomes and protection against corneal endothelial damage at the Annual Association for Research in Vision and Ophthalmology (ARVO) Meeting in New Orleans, April 23-27, 2023.

Key Points: 
  • Trefoil Therapeutics , a clinical-stage biotechnology company focused on restoring sight to people with corneal diseases, today announced multiple presentations providing evidence for clinical and preclinical efficacy of the company’s investigational medicine TTHX1114 for improving visual outcomes and protection against corneal endothelial damage at the Annual Association for Research in Vision and Ophthalmology (ARVO) Meeting in New Orleans, April 23-27, 2023.
  • “We aim to address an unmet clinical need with TTHX1114 by offering the potential to restore vision by stimulating and protecting the cornea’s own endothelial cells,” said David Eveleth, Ph.D., President and CEO of Trefoil Therapeutics.
  • His topic will be: The Role of Fibroblast Growth Factor derivatives in corneal endothelial regeneration which will be presented from 9:13-9:27 am.
  • Trefoil will also be present at booth #1156.

Zai Lab Announces Breakthrough Therapy Designation Granted for Bemarituzumab (FPA144) in China

Retrieved on: 
Tuesday, September 14, 2021
Risk, Amgen, HER2, SAN, Fibroblast growth factor, Quality of life, Stomach, Drug development, Forward-looking statement, Center, Health, Coronavirus, Infection, Center for Drug Evaluation and Research, Patient, National Medical Products Administration, Â, CDE, Oxaliplatin, Breakthrough therapy, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Organic acid, Head, OS, IHC, Neoplasm, ORR, Policy, NASDAQ, Breakthrough, GEJ, COVID-19, NMPA, NSCLC, GLOBE, Degenerative disease, Research, PFS, Prevalence, Pharmaceutical industry, Medical imaging, Fine chemical

In granting Breakthrough Therapy Designation, we are pleased to see that the CDE recognizes the promise of bemarituzumab.

Key Points: 
  • In granting Breakthrough Therapy Designation, we are pleased to see that the CDE recognizes the promise of bemarituzumab.
  • The Breakthrough Therapy Designation was granted based upon this subset of patients, based on IHC testing, showing at least 10% of tumor cells overexpressing FGFR2b.
  • Drugs that have been granted the Breakthrough Therapy Designation are prioritized by the CDE in communications, and in receiving guidance to promote the drug development progress.
  • Zai Lab has an exclusive license to develop and commercialize bemarituzumab in Greater China.

InnoCare Presents Latest Clinical Data of pan-FGFR Inhibitor Gunagratinib at the 2021 ASCO Annual Meeting

Retrieved on: 
Friday, June 4, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Branches of biology, Tyrosine kinase receptors, Fibroblast growth factor receptor, Cell biology, Asco, American Society of Clinical Oncology, Fibroblast growth factor, Biology

InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, presented the latest clinical data for the pan-FGFR inhibitor gunagratinib today at the 2021 American Society of Clinical Oncology (ASCO) annual meeting.

Key Points: 
  • InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, presented the latest clinical data for the pan-FGFR inhibitor gunagratinib today at the 2021 American Society of Clinical Oncology (ASCO) annual meeting.
  • This is the first time InnoCare has presented gunagratinibs clinical data at an international academic conference, showing good safety and tolerability.
  • ICP-192 (gunagratinib), developed by InnoCare Pharma, is a novel pan-FGFR (fibroblast growth factor receptors) inhibitor that potently and selectively inhibits FGFR activities irreversibly by covalent binding.
  • The 2021 ASCO Annual Meeting will be held online from June 4th to 8th, 2021.

Eisai: MHLW Grants Orphan Drug Designation in Japan to Novel FGF Receptor Selective Tyrosine Kinase Inhibitor E7090

Retrieved on: 
Monday, February 22, 2021
Tyrosine kinase receptors, Clusters of differentiation, Branches of biology, Cell biology, Biology, Fibroblast growth factor receptor 2, Fibroblast growth factor receptor 1, Fibroblast growth factor receptor, Fibroblast growth factor, Tyrosine kinase, Cholangiocarcinoma, Protein kinase inhibitor

In Japan, a Phase I clinical trial of E7090 was conducted, and E7090 has been designated as the target drug for the SAKIGAKE Designation System of the MHLW for the treatment of unresectable biliary tract cancer.

Key Points: 
  • In Japan, a Phase I clinical trial of E7090 was conducted, and E7090 has been designated as the target drug for the SAKIGAKE Designation System of the MHLW for the treatment of unresectable biliary tract cancer.
  • Discovered in-house by Eisai's Tsukuba Research Laboratories, E7090 is an orally available novel tyrosine kinase inhibitor that demonstrates selective inhibitory activity against fibroblast growth factor receptors (FGFR) FGFR1, FGFR2 and FGFR3.
  • et al., "Biliary tract cancer registry in Japan from 2008 to 2013", J Hepatobiliary Pancreat Sci., 2016, 23, 149-157.
  • (6) Arai Y. et al., "Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma", Hepatology, 2014, 59, 1427-1434.

Incyte Announces Positive CHMP Opinion for Pemigatinib for the Treatment of Adults With Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma With a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement

Retrieved on: 
Friday, January 29, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Clinical medicine, Medicine, Branches of biology, Breakthrough therapy, Orphan drugs, Tyrosine kinase receptors, Hepatology, Pemigatinib, Cholangiocarcinoma, Fibroblast growth factor receptor 2, Fibroblast growth factor

The CHMP opinion is based on data from the FIGHT-202 study evaluating the safety and efficacy of pemigatinib in adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with documented FGF/FGFR status.

Key Points: 
  • The CHMP opinion is based on data from the FIGHT-202 study evaluating the safety and efficacy of pemigatinib in adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with documented FGF/FGFR status.
  • If approved, pemigatinib will be the first targeted treatment in the EU indicated for patients with unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement and would be commercialized under the brand name Pemazyre.
  • Patients with cholangiocarcinoma are often diagnosed at a late or advanced stage when the prognosis is poor1,2.
  • FIGHT-302 is a Phase 3 study investigating pemigatinib as a first-line treatment for patients with cholangiocarcinoma with FGFR2 fusions or rearrangements.

Trefoil Therapeutics to Present Update on Regenerative Treatments for Corneal Diseases

Retrieved on: 
Monday, November 2, 2020
Biotechnology, Pharmaceutical, Optical, Health, Branches of biology, Fibroblast growth factor, Morphogens, FGF1, Growth factor, Biology

Trefoil Therapeutics announced today it will provide an update on the company and its clinical program for TTHX1114 at the upcoming Eyecelerator virtual conference.

Key Points: 
  • Trefoil Therapeutics announced today it will provide an update on the company and its clinical program for TTHX1114 at the upcoming Eyecelerator virtual conference.
  • TTHX1114 is the companys first-in-class, engineered fibroblast growth factor 1 (FGF-1), for the regenerative treatment of corneal diseases.
  • Trefoil also has a topical product based on its engineered FGF-1 that is in preclinical development for the treatment of corneal epithelial disorders.
  • Trefoil Therapeutics is a private biotechnology company focused on leveraging its engineered fibroblast growth factor-1 protein technology platform to develop first-in-class pharmacologic treatments for serious corneal endothelial diseases and epithelial disorders.

Basilea reports data from poster presentations at ESMO Virtual Congress 2020

Retrieved on: 
Tuesday, September 22, 2020
Tyrosine kinase receptors, Branches of biology, Clusters of differentiation, Basilea Pharmaceutica, Cell biology, Fibroblast growth factor receptor 1, Biology, European Society for Medical Oncology, Fibroblast growth factor receptor, Fibroblast growth factor

Basilea Pharmaceutica Ltd. (SIX: BSLN) today reports on several e-posters with new preclinical and clinical data on its fibroblast growth factor receptor (FGFR) inhibitor derazantinib and its tumor checkpoint controller, lisavanbulin, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which took place from 19-21 September, 2020.

Key Points: 
  • Basilea Pharmaceutica Ltd. (SIX: BSLN) today reports on several e-posters with new preclinical and clinical data on its fibroblast growth factor receptor (FGFR) inhibitor derazantinib and its tumor checkpoint controller, lisavanbulin, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which took place from 19-21 September, 2020.
  • In addition, gastric and lung cancer models showed the strongest correlation of FGFR1-3 expression versus the anticancer activity of derazantinib.
  • The results support the planned clinical investigation of derazantinib in gastric cancer as its next indication.
  • Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN).

Everest Medicines Announces First Patient Dosed in a Phase 1b/2 Study of FGF401 in Combination with Pembrolizumab for the Treatment of Advanced Solid Tumors

Retrieved on: 
Friday, August 7, 2020
Branches of biology, Tyrosine kinase receptors, Biology, Life sciences, Clusters of differentiation, Peptide hormones, Growth factors, FGF19, Novartis, Fibroblast growth factor

FGF401 is an ATP-competitive, reversible-covalent inhibitor of fibroblast growth factor receptor 4, or FGFR4, for which Everest Medicines obtained global development and commercial rights from Novartis AG, or Novartis.

Key Points: 
  • FGF401 is an ATP-competitive, reversible-covalent inhibitor of fibroblast growth factor receptor 4, or FGFR4, for which Everest Medicines obtained global development and commercial rights from Novartis AG, or Novartis.
  • Growing evidence demonstrates that the activation of the FGF19-FGFR4 pathway is associated with the formation of solid tumors.
  • FGF401 is an ATP-competitive, reversible-covalent inhibitor of FGFR4 for which Everest Medicines obtained exclusive global development and commercial rights from Novartis.
  • Everest is developing FGF401 as a potential new treatment for HCC and other solid tumors associated with activation of the FGF19-FGFR4 pathway.